ASX:CUV
ASX:CUVBiotechs

Clinuvel Pharmaceuticals (ASX:CUV): Valuation Check After Vallaurix Expansion to Boost Peptide Drug Development

Clinuvel Pharmaceuticals (ASX:CUV) is in the spotlight after unveiling a major expansion of its Vallaurix innovation hub in Singapore. The company has announced a five year push backed by the Economic Development Board to accelerate advanced peptide drug development. See our latest analysis for Clinuvel Pharmaceuticals. The market seems to be warming to that strategy, with a 30 day share price return of 17.15% and a 90 day gain of 21.11%. However, the five year total shareholder return...
ASX:BFG
ASX:BFGCapital Markets

ASX Penny Stocks To Consider In December 2025

As the Australian market experiences a mixed performance with materials leading and IT and industrials lagging, investors are keenly observing sector shifts. The term 'penny stocks' might feel like a relic of past market eras, but the potential they represent is as real as ever. Typically referring to smaller or relatively new companies, these stocks can provide a mix of affordability and growth potential when paired with strong financials.
ASX:ILU
ASX:ILUMetals and Mining

Iluka Resources (ASX:ILU) Is Down 8.9% After Pulling 2025 Synthetic Rutile Guidance Over Customer Uncertainty

In recent days, Iluka Resources withdrew its 2025 synthetic rutile production guidance due to uncertainty over a key UK customer agreement, prompting analyst downgrades and highlighting ongoing operational and market disruptions affecting its mineral sands and rare earths business. This shift draws attention to how sensitive Iluka’s outlook is to individual customer contracts, production reliability, and evolving tariffs and export controls in its core markets. We’ll now examine how the...
ASX:IMM
ASX:IMMBiotechs

Immutep (ASX:IMM): Valuation Check After Dr. Reddy’s Licensing Deal and New Phase II Breast Cancer Data

Immutep (ASX:IMM) has jumped onto investors radar after two meaningful updates: a lucrative licensing deal with Dr. Reddy’s for its cancer immunotherapy efti, and fresh Phase II breast cancer data reinforcing its development pathway. See our latest analysis for Immutep. The recent licensing deal and upbeat breast cancer data appear to have flipped sentiment, with a 1 month share price return of 25.49 percent and a 90 day share price return of 36.17 percent standing in contrast to a still...
ASX:APA
ASX:APAGas Utilities

What APA Group (ASX:APA)'s Brigalow Peaking Power Deal With CS Energy Means For Shareholders

In late November 2025, APA Group announced a special call to discuss its Joint Development Agreement with CS Energy to develop and own the proposed Brigalow Peaking Power Plant. This collaboration highlights APA Group’s push further into peaking power generation, potentially enhancing its role in supporting grid reliability alongside renewables. We’ll now explore how the Brigalow peaking power partnership with CS Energy may reshape APA Group’s existing investment narrative and risk...
ASX:RPL
ASX:RPLCapital Markets

3 Promising ASX Penny Stocks With Under A$2B Market Cap

As Australian shares prepare for a mid-week rise, the market remains attentive to interest rate decisions both locally and in the U.S., with investors weighing their options amidst economic uncertainties. In this context, penny stocks—though often seen as relics of past market trends—still capture attention for their potential to unlock growth in lesser-known corners of the market. By focusing on companies with strong financial health, investors can find opportunities that balance stability...